drug

axatilimab

Marketedupdated 3mo ago

by $INCY INCYTE CORP

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying axatilimab

phase2A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)recruitingn=296
phase2Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Diseaserecruitingn=49
phase2ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiationnot yet recruitingn=34
phase2Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiationrecruitingn=35
phase1Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AMLnot yet recruitingn=32
phase2Axatilimab for Sclerotic Chronic Graft-versus-Host Diseaserecruitingn=50
phase2MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)active not recruitingn=145
phase2A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Diseaserecruitingn=120

more trials →

News(1)

Incyte cuts early-stage cancer drug to focus on next-gen programs
Investors are focused on Incyte’s late-stage programs as the biotech braces for the 2028 patent cliff of its leading product Jakafi.
biospace · 19d ago

Data sources

ClinicalTrials.gov

last refreshed 19m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

axatilimab

Marketedupdated 3mo ago

by $INCY INCYTE CORP

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying axatilimab

phase2A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)recruitingn=296
phase2Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Diseaserecruitingn=49
phase2ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiationnot yet recruitingn=34
phase2Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiationrecruitingn=35
phase1Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AMLnot yet recruitingn=32
phase2Axatilimab for Sclerotic Chronic Graft-versus-Host Diseaserecruitingn=50
phase2MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)active not recruitingn=145
phase2A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Diseaserecruitingn=120

more trials →

News(1)

Incyte cuts early-stage cancer drug to focus on next-gen programs
Investors are focused on Incyte’s late-stage programs as the biotech braces for the 2028 patent cliff of its leading product Jakafi.
biospace · 19d ago

Data sources

ClinicalTrials.gov

last refreshed 19m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

axatilimab

all catalysts(0)

Trials studying axatilimab

News(1)

Report a data issue

comments(0)

axatilimab

all catalysts(0)

Trials studying axatilimab

News(1)

Report a data issue

comments(0)